Unlock instant, AI-driven research and patent intelligence for your innovation.

Insulin and pramlintide delivery systems, methods, and devices

A delivery device, pramlintide technology, applied in the field of physiological glucose concentration control, can solve the problem of lack of special control methods to deal with sudden and slow changes in blood glucose dynamics

Pending Publication Date: 2021-02-02
ELI LILLY & CO
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current AP systems lack controls that specifically address sudden and slow changes in glycemic dynamics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Insulin and pramlintide delivery systems, methods, and devices
  • Insulin and pramlintide delivery systems, methods, and devices
  • Insulin and pramlintide delivery systems, methods, and devices

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0090]Certain embodiments of the present disclosure relate to systems, methods, and devices for controlling physiological glucose concentrations in a closed-loop system suitable for use with various types of drugs (e.g., insulin, pramlintide, glucagon )use together.

[0091] Pramlintide is an injectable drug and is an analog of amylin. Amylin is a hormone co-secreted by the pancreas of healthy individuals with insulin, but is deficient in people with type 1 diabetes. Co-injection of pramlintide and insulin at mealtimes has been shown to improve glycemic control by delaying gastric emptying, inhibiting nutrient-stimulated glucagon secretion, and increasing satiety. In addition, co-injection of pramlintide and insulin has been found to increase the time a patient spends in the target glucose range (eg, 3.9-10.0 mmol / L) as compared to insulin injection alone, as well as during the day and night without increasing Reduced glucose variability in case of hypoglycemic risk. For ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to systems and methods for controlling physiological glucose concentrations in a patient.

Description

[0001] related application [0002] This application claims priority to U.S. Provisional Application No. 62 / 688,742, filed June 22, 2018, which is incorporated herein by reference in its entirety. technical field [0003] The present disclosure relates to the control of physiological glucose concentration. More particularly, the present disclosure relates to closed loop systems and methods for controlling physiological glucose concentrations in patients using insulin and pramlintide. Background technique [0004] Subcutaneous insulin replacement therapy has been shown to be the option of choice for diabetes control. Insulin is administered via multiple daily injections or an infusion pump, where the dose is announced by capillary glucose measurements taken several times per day by a glucometer. This traditional approach is known to be imperfect, as day-to-day (and indeed, moment-to-moment) variability can be significant. Additionally, this approach can be burdensome for t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G16H40/63
CPCG16H40/63G16H20/17G16H50/20G16H40/60A61B5/14532A61B5/4839A61K38/28A61M5/142A61M5/1723A61M2005/14208A61M2230/201
Inventor A·M·海达尔
Owner ELI LILLY & CO